Globe Newswire

AstaZero*, in collaboration with several partners, including Terranet AB and Trafikverket, is launching a new project aimed at significantly improving traffic safety for automated vehicles. The project will run from May 2024 to May 2025 and is funded by Vinnova, Sweden's innovation agency.

FFI, Strategic Vehicle Research and Innovation, is a collaboration program between the government and the automotive industry. The purpose of the project "Verification Methods for... (continue reading...)

• CellEDIT Service represents a novel workflow leveraging FluidFM-mediated intranuclear nanoinjection of CRISPR/Cas9 components into single cells.
• Control of the amount and stoichiometry of RNP complexes could boost efficiency, particularly when targeting multiple loci simultaneously.
• Demonstrated preservation of general cell characteristics and functionality post-editing in both single and multiple KO clones in CHO-K1 cells.

GLATTBRUGG, Switzerland, May 29, 2024 (GLOBE... (continue reading...)

HOUSTON, May 29, 2024 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) (“VAALCO” or the “Company”) today announced that it has drilled, completed and brought onto production four wells in Canada.

Highlights:

• Safely and successfully drilled, completed and brought online four long lateral wells in Canada;
  • All wells were 2.75 mile lateral development wells;
  • Strong initial production rates of approximately 500 barrels of oil per day (“BOPD”) for... (continue reading...)

VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Cornish Metals Inc. (AIM/TSX-V: CUSN) (“Cornish Metals” or the “Company”), is pleased to report that it has filed a technical report pursuant to National Instrument 43-101 – Standards for Disclosure for Mineral Projects (“NI 43-101”) for its 100% owned and permitted South Crofty tin project in Cornwall, United Kingdom under Cornish Metals’ profile on Sedar+ (www.sedarplus.com). The... (continue reading...)

ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential

BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I/II study evaluating the safety and clinical activity of ANV600 has been accepted... (continue reading...)